Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

AGENERASE

AMPRENAVIR

Standard Dose
50MG
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview AGENERASE is listed in Drugs@FDA under application 021007 (NDA).

Marketing status: Discontinued Active ingredient AMPRENAVIR Form and strength CAPSULE;ORAL - 50MG Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2005-11-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview AGENERASE is listed in Drugs@FDA under application 021007 (NDA). Marketing status: Discontinued Active ingredient AMPRENAVIR Form and strength CAPSULE;ORAL - 50MG Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2005-11-04 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.
AGENERASE (AMPRENAVIR) | Drug Monograph | MedicHelpline